期刊文献+

NGR多肽修饰的脂质体及其抗肿瘤研究进展 被引量:4

Advance in studies on NGR peptide modified liposome and its anti-tumor performance
原文传递
导出
摘要 NGR多肽是一种能与肿瘤新生血管内皮细胞上的CD13受体结合的靶向肽。将NGR多肽与脂质体相连接,得到NGR多肽修饰的脂质体。通过静脉注射该脂质体,NGR多肽能与肿瘤新生血管上的CD13受体结合,将脂质体定位于肿瘤组织,使得脂质体中的药物浓集于肿瘤部位,从而提高抗肿瘤效果。该文从NGR多肽入手,对NGR多肽的定义、NGR多肽修饰的脂质体、NGR多肽修饰的脂质体抗肿瘤的优势和不足、NGR多肽修饰的脂质体的最新研究方向等进行了综述,并对NGR多肽修饰的脂质体未来的研究进行了展望。 Aspargine-glycine-arginine (NGR) -containing peptides are targeted peptides which can be integrated with CD13 re- ceptors on tumor vascular endothelial cells. NGR peptides are connected to liposomes to obtain NGR peptide-modified liposomes. By intravenous injection of these liposomes, NGR peptides can be combined with CD13 receptors on tumor vascular endothelial cells, posi- tion liposomes in tumor tissues, and concentrate drug in liposomes in tumor, so as to enhance the antitumor effect. The article starts with NGR peptides, summarizes definition of NGR, NGR peptide-modified liposomes, strengths and weaknesses of NGR peptide-modi- fied liposomes in antitumor and the latest study orientation of NGR peptide-modified liposomes, and looks into the future of studies on NGR peptide-modified liposomes.
出处 《中国中药杂志》 CAS CSCD 北大核心 2013年第13期2041-2045,共5页 China Journal of Chinese Materia Medica
基金 国家自然科学基金项目(30701111 81001644) 广东省自然科学基金项目(10451040701004643) 江苏高校优势学科建设工程项目[PAPD(ysxk-2010)] 南京中医药大学中药学一级学科开放课题项目(2011ZYX3-003)
关键词 NGR多肽 NGR多肽修饰的脂质体 CD13受体 抗肿瘤 NGR peptide NGR petide-modified liposomes CD13 receptor antitumor
  • 相关文献

参考文献2

二级参考文献13

  • 1Reddy J, Low P. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. Journal of Controlled Release, 2000, 64(1-3): 27-37.
  • 2Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integnns. Nature Biotechnology, 1995, 13(3): 265-270.
  • 3Ross J, Fletcher J. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Elsevier, 1999.
  • 4Song S, Liu D, Peng J, Deng H, Guo Y, Xu L, Miller A, Xu Y. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. The FASEB Journal, 2009, 23(5): 1396.
  • 5Kullberg E, Bergstrand N, Carlsson J, Edwards K, Johnsson M, Sjoberg S, Gedda L. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjugate Chem, 2002, 13(4): 737-743.
  • 6Allen T, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mole Biol Let, 2002, 7(2): 217-219.
  • 7Moreira J, Ishida T, Gaspar R, Allen T. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharmaceutical research, 2002, 19(3): 265-269.
  • 8Ishida T, Iden D, Allen T. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS letters, 1999, 460(1): 129-133.
  • 9Dos Santos N, Allen C, Doppen A, Anantha M, Cox K, Gallagher R, Karlsson G, Edwards K, Kenner G, Samuels L. Influence of poly (ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. BBA- Biomembranes, 2007, 1768(6): 1367-1377.
  • 10De Menezes L, Daniel E, Pilarski L, Allen T. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer research, 1998, 58(15): 3320.

共引文献16

同被引文献24

  • 1丁怡,张建成,侯立军,张杰,王秋林,王树人.雷公藤甲素对血管生成的抑制作用[J].生物医学工程学杂志,2005,22(4):778-781. 被引量:17
  • 2Santos AO, da Silva LC, Bimbo LM, et al. Design ofpeptide- targeted liposomes containing nucleic acids [J]. Biochim Biophys Acta, 2010, 1798 (3): 433-441.
  • 3Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis [J]. Cancer Res, 2000, 60 (3): 722-727.
  • 4Chen J, Yan G J, Hu RR, et al. Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine [J]. Int J Nanomedicine, 2012, 7: 3567-3577.
  • 5Ndinguri MW, Zheleznyak A, Lauer JL, et al. Application of collagen-model triple-helical peptide-amphiphiles for CD44- targeted drug delivery systems [J]. JDrug Deliv, 2012, 2012: 592-602.
  • 6Nallamothu R, Wood GC, Pattillo CB, et al. A tumor vascu- lature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation [J]. AAPS PharmSciTech, 2006, 7 (2) : E7-E 16.
  • 7Kim MS, Lee DW, Park K, et al. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD- conjugated thermosensitive liposomes [J]. Colloids SurfB Biointerfaces, 2014, 116:17-25.
  • 8胡展红,石琦,张学农.去甲斑蝥素脂质体的制备工艺优化及其药剂学性质研究[J].中国药房,2009,20(4):279-282. 被引量:9
  • 9吴超,郭伟英,张磊.甘草次酸衍生物修饰去甲斑蝥素脂质体的制备及其小鼠肝靶向性实验研究[J].中国药房,2009,20(28):2184-2186. 被引量:10
  • 10尹愈佳,王小双,唐洁,张莉,谢亮,刘瀚旻,何勤.八聚精氨酸修饰的载紫杉醇脂质体的制备工艺研究[J].华西药学杂志,2012,27(6):630-633. 被引量:4

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部